@article{grady_ernst_secoura_price_birkenheuer_vaden_lidbury_gould_steiner_tolbert_2023, title={Gastric pH and serum gastrin concentration in age-matched healthy dogs and dogs with chronic kidney disease}, volume={10}, ISSN={["1939-1676"]}, DOI={10.1111/jvim.16907}, abstractNote={AbstractBackgroundGastric hyperacidity and hypergastrinemia are purported to cause gastric ulceration in dogs with chronic kidney disease (CKD); however, no published studies have evaluated gastric pH with serum gastrin concentrations in dogs with CKD.HypothesisTo compare mean intragastric pH, mean percent pH distribution, and serum gastrin concentrations in dogs with CKD to age‐matched, healthy dogs. We hypothesized there would be no difference in mean gastric pH or serum gastrin between groups.AnimalsThirteen dogs with CKD; 10 aged‐matched healthy dogs.MethodsProspective, case‐control study. Serum chemistry, complete blood count, urinalysis, and serum gastrin concentrations were evaluated in all dogs before radiographic‐assisted gastric placement of a pH capsule. Forty‐eight‐hour continuous gastric pH monitoring was performed in all dogs. Serum gastrin concentration, mean pH, and mean percentage time that gastric pH was strongly acidic (pH <1 and pH <2) were compared between groups using a repeated measures mixed‐model ANOVA.ResultsNo significant differences were observed between groups for any pH measurements, including mean ± SD gastric pH (CKD, 2.37 ± 0.87; healthy, 2.39 ± 0.99; P > .05). Serum gastrin concentrations were not significantly different between groups (median [range]: CKD, 10.5 ng/dL [<10‐17.1]; healthy, 10.9 ng/dL [<10‐15]; P > .05).Conclusions and Clinical ImportanceOur client‐owned dogs with CKD did not have lower gastric pH or higher serum gastrin concentrations compared to healthy dogs. Our results suggest that prophylactic gastric acid suppression in dogs with CKD is not warranted unless other clinical indications for use are present.}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={Grady, Kylie and Ernst, Eli and Secoura, Patricia L. and Price, Josh and Birkenheuer, Adam and Vaden, Shelly L. and Lidbury, Jonathan and Gould, Emily and Steiner, Jeorg M. and Tolbert, M. Katherine}, year={2023}, month={Oct} }
 @article{price_slead_secoura_kendall_vaden_2023, title={Lesser vestibular periurethral gland-like inflammation associated with lower urinary tract signs in a female dog}, ISSN={["1939-1676"]}, DOI={10.1111/jvim.16889}, abstractNote={AbstractCase DescriptionA 4‐year‐old female spayed mixed breed dog presented with a 2‐year history of painful urination and recurrent hematuria.Clinical FindingsThe dog had a large sensitive bladder, palpation of which was followed by painful urination. Pollakiuria accompanied by vocalization were noted during observation of voiding.DiagnosticsCystoscopy identified a focal, rounded expansion of epithelial tissue in the right lateral aspect of the urethral papilla containing purulent material consistent with an abscess. A sample submitted for culture yielded growth of Staphylococcus pseudintermedius and Proteus mirabilis.Treatment and OutcomePurulent material was expelled by manual pressure during cystourethroscopy. Enrofloxacin (10 mg/kg PO q24h for 42 days) and carprofen (4.4 mg/kg PO q24h for 14 days) were initiated. Clinical signs resolved within 2 days.Clinical RelevanceInflammation in the region of the lesser vestibular paraurethral glands should be considered as a differential for female dogs presenting with chronic dysuria.}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={Price, Matthew and Slead, Tanner S. and Secoura, Patricia L. and Kendall, Allison R. and Vaden, Shelly L.}, year={2023}, month={Sep} }
 @article{vaden_mathews_yoo_williams_harris_secoura_robertson_gleason_reynolds_piedrahita_2022, title={The use of autologous skeletal muscle progenitor cells for adjunctive treatment of presumptive urethral sphincter mechanism incompetence in female dogs}, volume={8}, ISSN={["1939-1676"]}, url={http://dx.doi.org/10.1111/jvim.16505}, DOI={10.1111/jvim.16505}, abstractNote={AbstractBackgroundUrethral sphincter mechanism incompetence (USMI) is a common problem in female dogs, but some dogs fail to achieve continence with standard treatment. Urethral submucosal injection of autologous skeletal muscle progenitor cells (skMPCs) previously has been shown to restore urethral function in a canine model of USMI.Hypothesis/ObjectiveTo determine if urethral submucosal injection of skMPC alters continence in dogs with USMI that had previously failed standard medical management. We hypothesized that the injections would lead to improved continence.AnimalsFifteen client‐owned dogs with USMI that had failed standard medical management.MethodsDogs were prospectively enrolled into a single‐armed clinical trial. Once enrolled, a triceps muscle of each dog was biopsied; the tissue specimens were digested, cultured, and expanded to 100 million cells before injection into the urethral submucosa using a surgical approach. Continence was assessed at baseline and 3, 6, 12, and 24 months post‐injection using continence scores and urethral pressure profilometry.ResultsMedian continence scores increased significantly from baseline at 3, 6, 12, and 24 months. Increases were seen in 14 of 15 dogs with 7, 6 or 1 dog achieving scores of 5, 4 or 3, respectively. Additional medication was required to achieve continence in all but 2 dogs.Conclusions and Clinical ImportanceUrethral submucosal injection of skMPC can be used adjunctively to improve continence in dogs with difficult to manage USMI. The procedure is labor intensive but well tolerated; most dogs will require continued medication to remain continent.}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, publisher={Wiley}, author={Vaden, Shelly L. and Mathews, Kyle G. and Yoo, James and Williams, James Koudy and Harris, Tonya and Secoura, Patty and Robertson, James and Gleason, Katherine L. and Reynolds, Hannah and Piedrahita, Jorge}, year={2022}, month={Aug} }
 @article{spencer_quimby_price_maclane_hillsman_secoura_steiner_tolbert_2021, title={Appetite-stimulating effects of once-daily omeprazole in cats with chronic kidney disease: Double-blind, placebo-controlled, randomized, crossover trial}, ISSN={["1939-1676"]}, DOI={10.1111/jvim.16268}, abstractNote={AbstractBackgroundCats with moderate to advanced chronic kidney disease (CKD) often display clinical signs such as vomiting and decreased appetite, and frequently receive omeprazole or other acid suppressants despite a lack of evidence to support their use.Hypothesis/ObjectivesTo evaluate the effect of once‐daily PO omeprazole on appetite in cats with CKD. We hypothesized that omeprazole would improve subjective appetite assessments in cats with CKD.AnimalsFourteen client‐owned cats with International Renal Interest Society (IRIS) stage 2 or 3 CKD and hyporexia.MethodsCats were prospectively enrolled in a multi‐institutional, double‐blinded, randomized, crossover study to evaluate the effect of a 14‐day trial of once‐daily PO omeprazole (1 mg/kg) or placebo (lactose gel capsule) on vomiting frequency and appetite. A daily log was completed by the owner during all treatment and rest periods to assess appetite using a subjective, qualitative, and 5‐point scoring system. Mixed model analyses of variance were performed to determine if average daily percentage food consumed or appetite score, as measured by subjective owner assessment, differed between treatments.ResultsCompared to placebo, a negligible but statistically significant difference in percentage of food consumed was observed between treatments (P = .04) with once‐daily omeprazole treatment resulting in a 2.7% increase in food consumption compared to placebo. No significant difference, however, was found in appetite score, body weight, or serum creatinine concentration between treatments.Conclusions and Clinical ImportanceOnce‐daily omeprazole does not markedly increase appetite in cats with CKD and should not be used as a first‐line treatment in the absence of evidence of gastrointestinal ulceration.}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={Spencer, Ashley and Quimby, Jessica M. and Price, Josh M. and MacLane, Sally and Hillsman, Shanna and Secoura, Patty and Steiner, Jorg M. and Tolbert, M. Katherine}, year={2021}, month={Sep} }
 @article{gin_secoura_harris_vaden_2020, title={Outcomes Following Balloon Dilation of Benign Urethral Strictures in Dogs: Eight Cases (2005-2018)}, volume={56}, ISSN={["1547-3317"]}, DOI={10.5326/JAAHA-MS-6935}, abstractNote={ABSTRACTBalloon dilation has been described infrequently as a treatment for benign urethral strictures in dogs but is often a first-line therapeutic option for humans. Additional evidence is needed to evaluate the potential role of this procedure in veterinary medicine. The aim of the study was to describe the techniques used and evaluate the response to balloon dilation of benign urethral strictures in dogs. Medical records were reviewed from eight client-owned dogs who underwent balloon dilation of a benign urethral stricture over a 13 yr period in this retrospective case series. Clinical signs improved for five of eight dogs after a single balloon dilation during a follow-up period of 1 wk to 3 yr. After a second procedure, an additional dog demonstrated improvement for 5.5 yr. Adverse outcomes included urinary incontinence in two dogs and recurrent bacteriuria in four dogs. Findings suggest that balloon dilation is an effective, minimally invasive procedure for the treatment of benign urethral strictures in dogs. Urinary incontinence, urinary tract infection, and stricture recurrence are potential outcomes for dogs undergoing this procedure either as a result of the nature of the underlying disease or as a result of the procedure.}, number={1}, journal={JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION}, author={Gin, Taylor Estes and Secoura, Patty and Harris, Tonya and Vaden, Shelly}, year={2020}, pages={23–29} }
 @article{bost_strynar_reiner_zweigenbaum_secoura_lindstrom_dye_2016, title={US domestic cats as sentinels for perfluoroalkyl substances: Possible linkages with housing, obesity, and disease}, volume={151}, ISSN={["1096-0953"]}, DOI={10.1016/j.envres.2016.07.027}, abstractNote={Perfluoroalkyl substances (PFAS), such as perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), are persistent, globally distributed, anthropogenic compounds. The primary source(s) for human exposure are not well understood although within home exposure is likely important since many consumer products have been treated with different PFAS, and people spend much of their lives indoors. Herein, domestic cats were used as sentinels to investigate potential exposure and health linkages. PFAS in serum samples of 72 pet and feral cats, including 11 healthy and 61 with one or more primary disease diagnoses, were quantitated using high-resolution time-of-flight mass spectroscopy. All but one sample had detectable PFAS, with PFOS and perfluorohexane sulfonate (PFHxS) ranging from <LOQ to 121 and <LOQ to 235 ng/mL, respectively. PFAS prevalence and geometric means in cats were very similar to contemporary NHANES reports of human sera in the U. S. population. The highest PFAS serum concentrations detected were in indoor cats due to disproportionately elevated PFHxS levels. Ranked by quartile, contingency testing indicated that total PFAS levels were positively associated with living indoors and with higher body weight and body condition scores. Individual PFAS quartile rankings suggested positive associations with respiratory effusion, thyroid, liver, and possibly chronic kidney disease. Domestic cats appear to be useful sentinels for assessing primary PFAS exposure routes, especially indoor sources of relevance to children. Additional case-control studies in pet cats are warranted to better define the potential health associations observed herein. A "One Health" approach assessing humans, pets, and their common environment may improve our understanding of chronic low-level, largely indoor, PFAS exposure and effects in humans and animals alike.}, journal={ENVIRONMENTAL RESEARCH}, author={Bost, Phillip C. and Strynar, Mark J. and Reiner, Jessica L. and Zweigenbaum, Jerry A. and Secoura, Patricia L. and Lindstrom, Andrew B. and Dye, Janice A.}, year={2016}, month={Nov}, pages={145–153} }